Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity

BJU International

Volumn 102, Issue SUPPL. 1, 2008, Pages 17-19

  Sangster, Philippa ^b   Kalsi, Vinay ^a,b  

^a NHNN ^*  (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MECHANISM; HEALTH ECONOMICS; HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT SURVEY;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXIN TYPE A; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 48149115710     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07824.x     Document Type: Review

References (21)

1. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004 13 : 437 52
2. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 2001 323 : 1300 3
3. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78
4. Schurch B, de Sèze M, Denys P et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005 174 : 196 200
5. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007 177 : 2231 6
6. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005 174 : 984 9
7. Reitz A, Stöhrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004 45 : 510 5
8. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006 68 : 1193 7
9. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005 47 : 653 9
10. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type a and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006 49 : 528 35
11. Kalsi V, Popat RB, Apostolidis A et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2005 49 : 519 27
12. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003 92 : 325 6
13. Sahai A, Kalsi V, Khan MS, Fowler CJ. Techniques for the intradetrusor administration of botulinum toxin. BJU Int 2006 97 : 675 8
14. Curtis L, Netten A. Unit Costs of Health and Social Care 2004. PSSRU Personal Social Services Research Unit, 2004
15. Department of Health. NHS Reference costs Appendix 1 NHS trusts. http://www.dh.gov.uk/Home/fs/en
16. British Medical Association. British National Formulary 2005 : 49
17. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. NICE, 2004
18. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001 23 : 2038 49
19. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005 37 : 252 7
20. Lake JM, Wong RK. Review article: the management of achalasia - a comparison of different treatment modalities. Aliment Pharmacol Ther 2006 24 : 909 18
21. Brisinda G, Cadeddu F, Brandara F, Marniga G, Maria G. Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure. Br J Surg 2007 94 : 162 7